TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19332208
Drug: Average glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average glucose > or =144 mg/dL (8 mmol/L)
Study: 21797816
Drug: Rimonabant 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimonabant 40 mg
Study: 21797816
Drug: Rimonabant (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimonabant (20 or 40 mg)
Study: 12730412
Drug: Betaine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaine (6 g daily for 6 weeks)
Study: 12730412
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (800 micro g daily for 6 weeks)
Study: 12730412
Drug: Placebo (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (6 g daily for 6 weeks)
Study: 2285608
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy using Flutamide and LHRH agonist (or orchiectomy) for an average of 771 days (24‐2607 days)
Study: 2285608
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy using Flutamide and LHRH agonist (or orchiectomy)
Study: 2285608
Drug: Monotherapy (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (not specified in detail)
Study: 393731
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg nickel supplements given on Monday and Tuesday of each week for at least 1 month
Study: 23905242
Drug: Modified group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified group: preoperative intramuscular injection of 50 mg dolantin, venous injection of 2 ml physiological saline, 10 mg dexamethasone, 5 mg ephedrine
Study: 23905242
Drug: Traditional group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional group: intramuscular injection of 10 mg diazepam prior to routine anesthesia
Study: 18758699
Drug: Nebivolol (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol (starting dose 2.5 mg once daily for 6 weeks)
Study: 18758699
Drug: Metoprolol (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (starting dose 25 mg once daily for 6 weeks)
Study: 16644608
Drug: timolol-latanoprost combination
Normalized name: latanoprost / timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: timolol-latanoprost combination
Study: 29866467
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (solifenacin succinate 5mg plus mirabegron 50mg)
Study: 20164553
Drug: Radiofrequency field
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiofrequency field exposure (890-MHz GSM signal, specific absorption rate of 1.0 Watt/kg) for 30 minutes
Study: 20164553
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of oral snuff
Study: 17662037
Drug: Active immunotherapy
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active immunotherapy with Alternaria alternata extract
Study: 10561949
Drug: Tropisetron 5
Normalized name: tropisetron 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron 5 mg plus dexamethasone 8 mg i.v. on day 1 followed by tropisetron 5 mg p.o. plus dexamethasone 4 mg orally bid on day 2‐6 (group I)
Study: 10561949
Drug: Tropisetron 5
Normalized name: tropisetron 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron 5 mg p.o. alone on day 2‐6 (group II)
Study: 31744796
Drug: Cord blood
Normalized name: CORD BLOOD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cord blood serum (CBS) eyedrops administered eight times/day for 1 month
Study: 31744796
Drug: Peripheral adult
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral adult donor blood serum (PBS) eyedrops administered eight times/day for 1 month
Study: 31744796
Drug: CBS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBS treatment
Study: 24219189
Drug: Motor learning
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Motor learning program (goal-oriented stepping and walking, strength training, twice weekly for 1 hour for 12 weeks)
Study: 24219189
Drug: Standard exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard exercise program (endurance training by treadmill walking, strength training, twice weekly for 1 hour for 12 weeks)
Study: 21209239
Drug: Fostamatinib (R788)
Normalized name: fostamatinib
DrugBank: Fostamatinib (DB12010)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fostamatinib (R788) 100 mg orally, twice daily from days 4 to 8 and once daily on days 3 and 9.
Study: 21209239
Drug: Matching placebo,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo, twice daily from days 4 to 8 and once daily on days 3 and 9.
Study: 7939398
Drug: Cisapride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (5 mg four times daily)
Study: 7939398
Drug: Cimetidine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (200 mg four times daily)
Study: 29254749
Drug: Oral rehydrating
Normalized name: terpin hydrate Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydrating fluids (GIII)
Study: 24366750
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg oseltamivir
Study: 24366750
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg oseltamivir
Study: 24366750
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of oseltamivir (75 mg and 150 mg)
Study: 24366750
Drug: Standard dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosing of oseltamivir
Study: 20660039
Drug: Postoperative TSH
Normalized name: TSH-releasing hormone
DrugBank: Protirelin (DB09421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative TSH suppression therapy (group A) with L-T(4) to keep serum TSH levels below 0.01 μU/ml
Study: 16199249
Drug: Levofloxacin 750
Normalized name: levofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 750 mg/d for 5 days
Study: 15032259
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg bupropion SR daily and PTC
Study: 15032259
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg bupropion SR daily and TM
Study: 15032259
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg bupropion SR daily and PTC
Study: 15032259
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg bupropion SR daily and TM
Study: 15032259
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg bupropion SR
Study: 15032259
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg bupropion SR
Study: 11054442
Drug: Ceftazidime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (2 g every 8 hours)
Study: 1577054
Drug: DuP-753 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: DuP-753 25 mg
Study: 1577054
Drug: DuP-753 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: DuP-753 50 mg
Study: 1577054
Drug: DuP-753 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: DuP-753 100 mg
Study: 1577054
Drug: DuP-753 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: DuP-753 200 mg
Study: 1577054
Drug: DuP-753 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: DuP-753 100 mg (multiple doses)
Study: 3298069
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of anti-lipid A
Study: 26172395
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 1800 mg orally for 4 months
Study: 16846541
Drug: Budesonide HFA
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide HFA pMDI 200 mug twice daily
Study: 16846541
Drug: Budesonide CFC
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide CFC pMDI 200 mug twice daily
Study: 16846541
Drug: Both budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Both budesonide formulations (HFA and CFC)
Study: 10465472
Drug: Endobronchial treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endobronchial treatment (brachytherapy, laser resection, or cryotherapy)
Study: 7840053
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of epoprostenol plus conventional therapy
Study: 627191
Drug: 0.9% sodium
Normalized name: LMD with 0.9% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride solution (physiological saline)
Study: 22624834
Drug: Pause-dependent augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pause-dependent augmentation of J waves during storms of VF
Study: 22624834
Drug: Pause-dependent augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pause-dependent augmentation of J waves after sudden R-R prolongation
Study: 22624834
Drug: Pause-dependent augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pause-dependent augmentation of J waves
Study: 18524974
Drug: Iodixanol-270 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodixanol-270 (60 mL intravenous bolus)
Study: 16632399
Drug: Concurrent chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemotherapy (CT) with radiation therapy (RT) - mitoxantrone (12 mg/m2), 5-FU (500 mg/m2), cyclophosphamide (500 mg/m2), 6 cycles, first 3 cycles of CT with RT
Study: 16632399
Drug: Sequential chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemotherapy (CT) followed by radiation therapy (RT) - mitoxantrone (12 mg/m2), 5-FU (500 mg/m2), cyclophosphamide (500 mg/m2), 6 cycles, RT started 3 to 5 weeks after the 6th cycle of CT
Study: 10228604
Drug: Echinaforce (Echinacea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echinaforce (Echinacea purpurea-preparation from 95% herba and 5% radix)
Study: 10228604
Drug: Special Echinacea
Normalized name: Echinacea
DrugBank: Echinacea (DB14240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Special Echinacea purpurea radix preparation
Study: 8904594
Drug: Nasal inhalation
Normalized name: Nasal Inhalant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal inhalation of cold dry air (‐4 degrees C)
Study: 8904594
Drug: Nasal inhalation
Normalized name: Nasal Inhalant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal inhalation of cold dry air (‐10 degrees C)
Study: 8904594
Drug: Nasal inhalation
Normalized name: Nasal Inhalant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal inhalation of dry air (0.3% RH)
Study: 8904594
Drug: Nasal inhalation
Normalized name: Nasal Inhalant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal inhalation of moist room air (97% RH)
Study: 8904594
Drug: Oral breathing
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral breathing of cold dry air, dry air, or moist air
Study: 8904594
Drug: Nasal anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal anesthesia or inhalation of a cholinergic antagonist before cold air
Study: 1930699
Drug: Acetaminophen 650
Normalized name: acetaminophen 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 650 mg with codeine 60 mg
Study: 29604620
Drug: Caricol®-Gastro (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caricol®-Gastro (20 g, taken twice per day for 30 days)
Study: 18564687
Drug: Combined DTPw‐HBV/Hib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined DTPw‐HBV/Hib vaccine administered at 1.5, 3, and 5 months after a birth dose of hepatitis B vaccine (HBV)
Study: 12718838
Drug: Combined DTPw‐HBV/Hib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined DTPw‐HBV/Hib vaccine
Study: 15958628
Drug: Marimastat 5
Normalized name: Marimastat
DrugBank: Marimastat (DB00786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marimastat 5 mg
Study: 15958628
Drug: Marimastat 20
Normalized name: Marimastat
DrugBank: Marimastat (DB00786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marimastat 20 mg
Study: 15958628
Drug: Marimastat 40
Normalized name: Marimastat
DrugBank: Marimastat (DB00786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marimastat 40 mg
Study: 15958628
Drug: Marimastat (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marimastat (all doses)
Study: 10501821
Drug: Ciprofloxacin (CPF)
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin (CPF) 600 mg t.i.d.
Study: 30499486
Drug: Bioresonance therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioresonance therapy (BRT)
Study: 17628912
Drug: Betamethasone 0.6
Normalized name: betamethasone 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone 0.6 mg/day (n=8) or methylprednisolone 4 mg/day (n=6), single daily oral dose at 11.00 PM for 30 days
Study: 17628912
Drug: Betamethasone 0.3
Normalized name: betamethasone 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone 0.3 mg, single daily dose at 11.00 PM for six months
Study: 17628912
Drug: Post-treatment evaluation
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment evaluation of 11 patients after therapy withdrawal
Study: 16149685
Drug: Cisapride (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (10 mg, tid ac for 2 weeks)
Study: 12115016
Drug: Nimesulide suspension
Normalized name: nimesulide Oral Suspension
DrugBank: Nimesulide (DB04743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide suspension 1.5 mg/kg per dose
Study: 7960533
Drug: ESWL monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESWL monotherapy
Study: 7960533
Drug: ESWL+PCNL combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESWL+PCNL combined therapy
Study: 3149152
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium (150 mg, 75 mg twice daily)
Study: 3149152
Drug: Aspirin (3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (3.6 g, 1.2 g three times daily)
Study: 18567822
Drug: Fluoxetine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (6 weeks administration)
Study: 18567822
Drug: Placebo (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (6 weeks administration)
Study: 15811211
Drug: gatifloxacin 0.3%
Normalized name: GATIFLOXACIN 0.3% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: gatifloxacin 0.3% administered BID
Study: 15811211
Drug: gatifloxacin 0.3%
Normalized name: GATIFLOXACIN 0.3% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: gatifloxacin 0.3% administered QID
Study: 11919461
Drug: 2% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lignocaine hydrochloride gel administered over 10 seconds
Study: 11919461
Drug: 2% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lignocaine hydrochloride gel administered over 2 seconds
Study: 9120744
Drug: Curosurf (modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curosurf (modified porcine surfactant) administered at birth (80 mg/ml; dose 20 mg/kg)
Study: 9120744
Drug: Curosurf (modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curosurf (modified porcine surfactant) administered at birth
Study: 6841943
Drug: Proglumide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proglumide (50 mg/kg bolus, 50 mg/kg hour infusion, 100 mg/kg hour infusion, or combination)
Study: 6841943
Drug: Cimetidine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (2 mg/kg I.V. followed by 2 mg/kg hour)
Study: 24362907
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg alpha-lipoic acid (ALA) three times a day orally for 24 weeks
Study: 17882685
Drug: New low‐
Approvals — FDA: no, EMA: no, PMDA: no
Description: New low‐ and ultra‐low‐dose oral preparations (0.3 mg conjugated equine estrogens and 0.5 mg estradiol)
Study: 17882685
Drug: 14 microg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 microg transdermal system
Study: 17882685
Drug: New progestogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: New progestogens (e.g. drospirenone, bioidentical progesterone, selective progesterone receptor modulators)
Study: 17882685
Drug: New female
Approvals — FDA: no, EMA: no, PMDA: no
Description: New female androgen patch
Study: 17882685
Drug: Selective estrogen
Normalized name: Selective estrogen receptor modulator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective estrogen receptor modulator/conjugated equine estrogen preparation combination
Study: 15083368
Drug: HRT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT with 0.625 mg oestrogen/day and 0.15 mg norgestrel
Study: 11228385
Drug: Pentavalent vaccine
Normalized name: rotavirus, live, pentavalent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentavalent vaccine (DTP-Hib-HB) plus placebo (Group A, n=619)
Study: 11228385
Drug: Quadrivalent vaccine
Normalized name: PAPILLOMAVIRUS HUMAN QUADRIVALENT VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent vaccine (DTP-HB) plus Hib vaccine (Group B, n=620)
Study: 11228385
Drug: Bivalent vaccine
Normalized name: PAPILLOMAVIRUS BIVALENT VACCINE INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent vaccine (Hib-HB) plus DTP (Group C, n=226)
Study: 11228385
Drug: Monovalent hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent hepatitis B vaccine at birth followed by pentavalent vaccine (Group E, n=460)
Study: 11228385
Drug: Licensed control
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Licensed control vaccines (DTP, Hib, HB) (Group D, n=231)
Study: 9828772
Drug: Metipranolol (topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metipranolol (topical and systemic application)
Study: 9828772
Drug: Metipranolol (topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metipranolol (topical application)
Study: 6106098
Drug: Diet B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet B (carbohydrate 53%, fibre 54 g)
Study: 6106098
Drug: Diet A
Normalized name: Diet Aid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet A (carbohydrate 53%, fibre 16 g)
Study: 6106098
Drug: Diet C
Normalized name: Diet Caplets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet C (carbohydrate 42%, fibre 20 g)
Study: 27771172
Drug: 250mg resveratrol
Normalized name: resveratrol 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250mg resveratrol daily for 3 months
Study: 24297381
Drug: Sarilumab 150
Normalized name: SARILUMAB 150MG/1.14ML INJ SYR 1.14ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarilumab 150 mg qw
Study: 31268376
Drug: Sarilumab 150
Normalized name: SARILUMAB 150MG/1.14ML INJ SYR 1.14ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarilumab 150 mg q2w
Study: 31268376
Drug: Sarilumab 200
Normalized name: SARILUMAB 200MG/1.14ML INJ SYR 1.14ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarilumab 200 mg q2w
Study: 24297381
Drug: Sarilumab ≥150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarilumab ≥150 mg q2w
Study: 30120894
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (control)
Study: 23140661
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (100 mg/day)
Study: 11720400
Drug: Swallowing reflex
Normalized name: Cuscuta reflexa extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Swallowing reflex measured by latent time (LT) for swallowing following bolus injection of distilled water.
Study: 8326162
Drug: Five-drug combination
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-drug combination (metoclopramide, thiethylperazine, diphenhydramine, dexamethasone, diazepam)
Study: 3511346
Drug: Naloxone 2
Normalized name: naloxone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone 2 mg IV
Study: 28987804
Drug: Revefenacin 700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revefenacin 700 μg
Study: 28987804
Drug: Ipratropium 500
Normalized name: ipratropium 500 mcg/2.5 mL inhalation solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipratropium 500 μg
Study: 28987804
Drug: Revefenacin 22
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revefenacin 22 μg
Study: 26560987
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg oral sustained release morphine daily for 4 days
Study: 16086046
Drug: Glutamine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine (2 g/m²/dose, maximum 4 g, twice daily until 28 days post transplant)
Study: 11897246
Drug: BCAA 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA 1.5 g
Study: 11897246
Drug: BCAA 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA 3.0 g
Study: 11897246
Drug: BCAA 6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA 6.0 g
Study: 11897246
Drug: BCAA (middle-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA (middle-dose group)
Study: 11897246
Drug: BCAA (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA (1.5 and 3.0 g)
Study: 10451133
Drug: Femoral 3-in-1
Normalized name: SUS SCROFA TEMPORAL LOBE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Femoral 3-in-1 block with 40 ml ropivacaine 0.2% and 20 ml ropivacaine 0.2% infiltration at the end of surgery
Study: 7587906
Drug: Chemotherapy protocol
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy protocol without VM-26 and CCNU
Study: 2112489
Drug: leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: leuprolide acetate depot, 3.75 mg intramuscularly every 28 days for four injections (n = 10)
Study: 110027
Drug: Disodium chromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium chromoglycate (DSCG) nasal spray (2%)
Study: 23709432
Drug: Nicorandil 12
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil 12 mg in 100 mL of 0.9% saline administered intravenously for 30 minutes prior to coronary angiography
Study: 21849080
Drug: 3-4 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-4 ml/kg BW/h 0.9% saline intravenously for 6 hours
Study: 21849080
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment consisting of unrestricted oral fluid intake